Log In
BCIQ
Print this Print this
 

actoxumab (CDA-1, MDX-066, MK-3415) (formerly MBL-CD1A)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHuman mAb against Clostridium difficile toxin A (TcdA)
Molecular Target Clostridium difficile toxin A (TcdA)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationDiarrhea (infectious)
Indication DetailsTreat Clostridium difficile-associated diarrhea (CDAD); Treat Clostridium difficile-associated diarrhea (CDAD) and prevent subsequent relapse
Regulatory Designation
PartnerMerck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$225.0M

$60.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/27/2009

$225.0M

$60.0M

Undisclosed

Get a free BioCentury trial today